click below
click below
Normal Size Small Size show me how
Mod 4 Week 2
PT chapter 10 review 2
| Question | Answer |
|---|---|
| Where are receptors located? | Receptors are located on the surfaces of cell membranes and inside cells. |
| What is "Site of Action"? | The location where an administered drug produces an effect. |
| "AGONISTS VS ANTAGONIST" Receptor that "ACTIVATE"? | AGONISTS are drugs that "ACTIVE" receptors to accelerate or slow normal cellular function. |
| "AGONISTS VS ATAGONIST 2" Receptors that "DO NOT ACTIVATE" | ANTAGONISTS bind to cell receptors, but DO NOT ACTIVATE them. |
| "FAT"? | "FAT" is the organ system expected to have lower blood concentration of the drug based on blood flow rates. |
| "THERAPEUTIC WINDOWS"? | Range between MEC and MTC. |
| "DURATION OF ACTION" | Time the drug should above the MED. Onset of Action. It is the time MEC is reached and the response occur. |
| "HOW DRUGS MOVE THROUGH THE BODY" "ABSORPTION" | Process by which refers to the transfer of a drug into the blood from an administered drug product. |
| "HOW DRUGS MOVE THROUGH THE BODY 2" "METABOLISM" | The body's process of transforming drugs. |
| "GASTRIC EMPTYING TIME"? | The TIME a drug will stay in the stomach before e it is emptied into the small intestine. |
| "ABSORPTION 2" | Intravenous administration does not have an ABSORPTION step. |
| "ABSORPTION 3" | When gastric contents SLOWS DOWN, it will take longer to move through the bowel, therefore increasing absorption. |
| "ABSORPTION 4" | Metabolizing enzymes in the GI tract wall will DECREASE absorption. |
| "ENZYMES"? | Complex proteins that causes chemical reactions in other substances. |
| "ENZYMES INHIBITION"? | Typically occurs in the liver. |
| "ENTEROHEPATIC CYCLING"? | Involves the transfer of drugs, and their metabolites from the liver to the intestines, and then back into CIRCULATION. |
| "ENZYME INDUCTION"? | The increase in ENZYMES activity that results in greater metabolism of drugs. |
| "KIDNEYS"? | The KIDNEYS filter the blood and remove waste materials including drugs and metabolites. |
| "BIOAVAILABILITY" | The relative amount of an administered dose that reaches the general circulation and the rate at which it occurs |
| "BIOEQUIVALENT DRUG PRODUCTS" | DRUGS PRODUCTS that contain identical amounts of the same active ingredients in the same dosage form, so they have same bioavailability. |
| "PHARMACEUTICAL ALTERNATIVE" | Same active ingredient. Amounts can be different. Dosage form can be different. Inactive ingredient can be different. |
| "ORANGE BOOK" FDA? | The FDA requires drug manufacturers to perform bioequvalency studies on their products before they are approved for marketing. |
| "MINIMUM EFFECTIVE CONCENTRATION"? | The blood concentration needed of a drug to produce a response. |
| "PASSIVE DIFFUSION"? | Is the most common way an orally administered drug is distributed through the body.The movement |
| "PASSIVE DIFFUSION 2"? | The movement of drugs from an area of higher concentration to a lower concentration. |
| "SELECTIVE ACTION"? | The characteristic of a drug that makes its action specific to certain receptors and the tissues they effect. |
| BINDING | Drugs BIND to may proteins in blood and tissue. |
| PLASMA PROTEIN BINDING | With PLASMA PROTEIN BINDING drug remains inactive. |
| BINDING RECEPTOR | BINDING with the RECEPTOR at the site of action, produces a response. |
| STRONGER BINDING | When a drug is displaced by a STRONGER BINDING drug, the unbound drug concentration will increase. |
| PROTEIN BINDING | PROTEIN BINDING can result in the gradual release of a drug into the bloodstream. |